Funding for this research was provided by:
Fonds Wetenschappelijk Onderzoek (1165119N, 1S46219N, Senior clinical investigatorship, G0F8516N)
ALS liga België (not applicable)
KU Leuven (‘Een hart voor ALS’, ‘Laeversfonds voor ALS onderzoek’ and ‘Valéry Perrier Race against ALS Fund’, C14-17-107)
Agentschap voor Innovatie door Wetenschap en Technologie (IWT 135043)
Mady Browaeys Fund (not applicable)
Received: 3 October 2019
Accepted: 11 November 2019
First Online: 2 December 2019
Ethics approval and consent to participate
: All human brain tissue was provided by the UZ Leuven brain biobank (Belgium) and the municipal hospital Offenbach (Germany) in accordance with the Belgian and German law and approved by local ethical committees. Ethical approval for the use of tissue from these cases for this study was granted by the UZ/KU-Leuven ethical committee (Belgium) (S60803).
: Not applicable for this study, which did not use person’s data. Only anonymized or pseudonymized data were processed.
: RV’s institution has a clinical trial agreement (RV as PI) with AbbVie (USA), Biogen (USA), Genentech (USA), Novartis (Switzerland), and Roche (Switzerland). PVD participated in advisory board meetings for Genzyme (USA), Pfizer (USA), Biogen (USA), Cytokinetics (USA), Mitsubishi Tanabe (Japan), CSL Behring (USA), Alexion Pharmaceuticals (USA). DRT received speaker honorary from Novartis Pharma AG (Switzerland), travel reimbursement from GE-Healthcare (UK) and UCB (BE), and collaborated with Novartis Pharma AG (Switzerland), Probiodrug (Germany), GE-Healthcare (UK), and Janssen Pharmaceutical Companies (Belgium).